Pharmacological management of diabetic dyslipidemia

Expert Review of Clinical Pharmacology

Volumn 10, Issue 2, 2017, Pages 187-200

  Filippatos, T D ^a   Florentin, M ^a   Georgoula, M ^a   Elisaf, M S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cardiovascular risk; cholesterol ester transfer protein; diabetic dyslipidemia; ezetimibe; fenofibrate; high density lipoprotein; proprotein convertase subtilisin kexin type 9; triglycerides

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PROPROTEIN CONVERTASE 9; SERINE PROTEINASE INHIBITOR; SMALL DENSE LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

CARBOHYDRATE METABOLISM; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DIABETIC DYSLIPIDEMIA; DIABETIC PATIENT; DYSLIPIDEMIA; HUMAN; LIPID METABOLISM; META ANALYSIS (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; COMBINATION DRUG THERAPY; DYSLIPIDEMIAS;

CHOLESTEROL, LDL; DIABETES MELLITUS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; HYPOLIPIDEMIC AGENTS;

EID: 85010058290     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1080/17512433.2017.1263565     Document Type: Review

References (211)

1. Rajalakshmi R, Prathiba V, Mohan V., Does tight control of systemic factors help in the management of diabetic retinopathy? Indian J Ophthalmol. 2016;64:62–68.
2. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women:meta-analysis of 37 prospective cohort studies. BMJ. 2006;332:73–78.
3. Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease:a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–2222.
4. Piepoli MF, Hoes AW, Agewall S, et al. European guidelines on cardiovascular disease prevention in clinical practice:the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315–2381.
5. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278.
6. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS):multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–696.
7. Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins:the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012;14:1–10.
8. Leiter LA, Lundman P, Da Silva PM, et al. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada:results of the Dyslipidaemia International Study. Diabet Med. 2011;28:1343–1351.
9. Ginsberg HN. Diabetic dyslipidemia:basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes. 1996;45(Suppl 3):S27–S30.
10. Jaiswal M, Schinske A, Pop-Busui R. Lipids and lipid management in diabetes. Best Pract Res Clin Endocrinol Metab. 2014;28:325–338.
11. Watts GF, Karpe F. Triglycerides and atherogenic dyslipidaemia:extending treatment beyond statins in the high-risk cardiovascular patient. Heart. 2011;97:350–356.
12. Sarwar N, Sandhu MS, Ricketts SL, et al. Triglyceride-mediated pathways and coronary disease:collaborative analysis of 101 studies. Lancet. 2010;375:1634–1639.
13. Taskinen MR. Diabetic dyslipidaemia:from basic research to clinical practice. Diabetologia. 2003;46:733–749.
14. Watts GF, Playford DA. Dyslipoproteinaemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus:an hypothesis. Atherosclerosis. 1998;141:17–30.
15. Stahlman M, Fagerberg B, Adiels M, et al. Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort:impact on small HDL particles. Biochim Biophys Acta. 2013;1831:1609–1617.
16. Le Goff W, Guerin M, Chapman MJ. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol Ther. 2004;101:17–38.
17. Gazi I, Tsimihodimos V, Filippatos T, et al. Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism. 2006;55:885–891.
18. Gazi I, Tsimihodimos V, Filippatos TD, et al. LDL cholesterol estimation in patients with the metabolic syndrome. Lipids Health Dis. 2006;5:8.
19. Lagos KG, Filippatos TD, Tsimihodimos V, et al. Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. Lipids. 2009;44:9–16.
20. Filippatos TD, Rizos EC, Tsimihodimos V, et al. Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A(2) in subjects with prediabetes. Lipids. 2013;48:547–555.
21. Yazdanyar A, Yeang C, Jiang XC. Role of phospholipid transfer protein in high-density lipoprotein- mediated reverse cholesterol transport. Curr Atheroscler Rep. 2011;13:242–248.
22. Persegol L, Verges B, Foissac M, et al. Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia. 2006;49:1380–1386.
23. Florentin M, Liberopoulos EN, Wierzbicki AS, et al. Multiple actions of high-density lipoprotein. Curr Opin Cardiol. 2008;23:370–378.
24. Annema W, Von Eckardstein A. Dysfunctional high-density lipoproteins in coronary heart disease:implications for diagnostics and therapy. Transl Res. 2016;173:30–57.
25. Tsimihodimos V, Gazi I, Filippatos T, et al. Plasma triglyceride levels and body mass index values are the most important determinants of prebeta-1 HDL concentrations in patients with various types of primary dyslipidemia. Atherosclerosis. 2010;208:506–511.
26. Filippatos TD, Elisaf MS. High density lipoprotein and cardiovascular diseases. World J Cardiol. 2013;5:210–214.
27. La Belle M, Krauss RM. Differences in carbohydrate content of low density lipoproteins associated with low density lipoprotein subclass patterns. J Lipid Res. 1990;31:1577–1588.
28. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002;43:1363–1379.
29. Tribble DL, Holl LG, Wood PD, et al. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis. 1992;93:189–199.
30. Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. Qjm. 2006;99:1–14.
31. Gazi IF, Tsimihodimos V, Tselepis AD, et al. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther. 2007;7:53–72.
32. Gazi I, Lourida ES, Filippatos T, et al. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem. 2005;51:2264–2273.
33. Gazi IF, Filippatos TD, Tsimihodimos V, et al. The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol. Lipids. 2006;41:647–654.
34. Gazi IF, Milionis HJ, Filippatos TD, et al. Hypertriglyceridaemic waist phenotype criteria and prevalent metabolic triad in women. Diabetes Metab Res Rev. 2008;24:223–230.
35. Stone NJ, Robinson JG, Lichtenstein AH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults:a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2013;2014(63):2889–2934.
36. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. acc expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk:a report of the American College of Cardiology Task Force on clinical expert consensus documents. J Am Coll Cardiol. 2016;2016(68):92–125.
37. American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care. 2015;38(Suppl):S1–S99.
38. Catapano AL, Graham I, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias:the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016. DOI:10.1093/eurheartj/ehw272
39. Wang ZH, Liu XL, Zhong M, et al. Pleiotropic effects of atorvastatin on monocytes in atherosclerotic patients. J Clin Pharmacol. 2010;50:311–319.
40. Murrow JR, Sher S, Ali S, et al. The differential effect of statins on oxidative stress and endothelial function:atorvastatin versus pravastatin. J Clin Lipidol. 2012;6:42–49.
41. Athyros VG, Kakafika AI, Tziomalos K, et al. Pleiotropic effects of statins-clinical evidence. Curr Pharm Des. 2009;15:479–489.
42. Krysiak R, Gdula-Dymek A, Bachowski R, et al. Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes. Diabetes Care. 2010;33:2266–2270.
43. Filippatos TD, Mikhailidis DP. Statins and heart failure. Angiology. 2008;59:58S–61S.
44. Agouridis AP, Tsimihodimos V, Filippatos TD, et al. High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia. Lipids. 2011;46:521–528.
45. Agouridis AP, Tsimihodimos V, Filippatos TD, et al. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia. Expert Opin Pharmacother. 2011;12:2605–2611.
46. Randomised trial of cholesterol lowering in. 4444 patients with coronary heart disease:the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389.
47. Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention:an analysis from the JUPITER trial. Lancet. 2012;380:565–571.
48. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med. 1996;335:1001–1009.
49. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREEk Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin. 2002;18:220–228.
50. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes:the MIRACL study:a randomized controlled trial. Jama. 2001;285:1711–1718.
51. Donner-Banzhoff N, Sonnichsen A. Statins and primary prevention of cardiovascular events. Bmj. 2008;337:a2576.
52. Mills EJ, Rachlis B, Wu P, et al. Primary prevention of cardiovascular mortality and events with statin treatments:a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52:1769–1781.
53. Amarenco P, Labreuche J. Lipid management in the prevention of stroke:review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8:453–463.
54. Delahoy PJ, Magliano DJ, Webb K, et al. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes:an updated meta-analysis. Clin Ther. 2009;31:236–244.
55. Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease:a network meta-analysis of 170,255 patients from 76 randomized trials. Qjm. 2011;104:109–124.
56. Ross SD, Allen IE, Connelly JE, et al. Clinical outcomes in statin treatment trials:a meta-analysis. Arch Intern Med. 1999;159:1793–1802.
57. Zhou Z, Rahme E, Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J. 2006;151:273–281.
58. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes:a randomised placebo-controlled trial. Lancet. 2003;361:2005–2016.
59. Knopp RH, d’Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes:the atorvastatin study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29:1478–1485.
60. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins:a meta-analysis. Lancet. 2008;371:117–125.•• A meta-analysis that showed the beneficial effect of cholesterol reduction in people with diabetes.
61. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy:a meta-analysis. Jama. 2011;305:2556–2564.
62. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;CD004816. doi:10.1002/14651858.
63. Costa J, Borges M, David C, et al. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients:meta-analysis of randomised controlled trials. Bmj. 2006;332:1115–1124.
64. Kiortsis DN, Filippatos TD, Mikhailidis DP, et al. Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis. 2007;195:7–16.
65. Leung A, Schaefer EW, Tempelhof MW, et al. Emphasizing statin safety in the hospitalized patient:a review. Am J Med. 2012;125:845–853.
66. Stein EA, Vidt DG, Shepherd J, et al. Renal safety of intensive cholesterol-lowering treatment with rosuvastatin:a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program. Atherosclerosis. 2012;221:471–477.
67. Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy:a meta-analysis of randomized trials. Cmaj. 2008;178:576–584.
68. Davidson MH, Clark JA, Glass LM, et al. Statin safety:an appraisal from the adverse event reporting system. Am J Cardiol. 2006;97:32C–43C.
69. Floyd JS, Heckbert SR, Weiss NS, et al. Use of administrative data to estimate the incidence of statin-related rhabdomyolysis. Jama. 2012;307:1580–1582.
70. Antons KA, Williams CD, Baker SK, et al. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med. 2006;119:400–409.
71. Florentin M, Elisaf MS. Simvastatin interactions with other drugs. Expert Opin Drug Saf. 2012;11:439–444.
72. Kei AA, Filippatos TD, Elisaf MS. The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia. Expert Opin Drug Saf. 2016;15:559–569.
73. Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms:impact on statin therapy-European Atherosclerosis Society consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015;36:1012–1022.
74. Kostapanos MS, Liamis GL, Milionis HJ, et al. Do statins beneficially or adversely affect glucose homeostasis? Curr Vasc Pharmacol. 2010;8:612–631.
75. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes:a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–742.
76. Filippatos TD, Elisaf MS. Pitavastatin and carbohydrate metabolism:what is the evidence? Expert Rev Clin Pharmacol. 2016;9:955–960.
77. Livingstone SJ, Looker HC, Akbar T, et al. Effect of atorvastatin on glycaemia progression in patients with diabetes:an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS). Diabetologia. 2016;59:299–306.
78. Erqou S, Lee CC, Adler AI. Statins and glycaemic control in individuals with diabetes:a systematic review and meta-analysis. Diabetologia. 2014;57:2444–2452.
79. Filippatos TD, Mikhailidis DP. Lipid-lowering drugs acting at the level of the gastrointestinal tract. Curr Pharm Des. 2009;15:490–516.
80. Mikhailidis DP, Sibbring GC, Ballantyne CM, et al. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin. 2007;23:2009–2026.
81. Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response:a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223:251–261.
82. Kalogirou M, Tsimihodimos V, Gazi I, et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin. 2007;23:1169–1176.
83. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol. 1997;80:106–107.
84. Nicholls SJ, Brandrup-Wognsen G, Palmer M, et al. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010;105:69–76.
85. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101:207–213.
86. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;40:2125–2134.
87. Ohbu-Murayama K, Adachi H, Hirai Y, et al. Ezetimibe combined with standard diet and exercise therapy improves insulin resistance and atherosclerotic markers in patients with metabolic syndrome. J Diabetes Investig. 2015;6:325–333.
88. Chang E, Kim L, Choi JM, et al. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition. Metabolism. 2015;64:633–641.
89. Kalogirou M, Tsimihodimos V, Elisaf M. Pleiotropic effects of ezetimibe:do they really exist? Eur J Pharmacol. 2010;633:62–70.
90. Nakou ES, Filippatos TD, Kiortsis DN, et al. The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opin Pharmacother. 2008;9:3151–3158.
91. Nakou ES, Filippatos TD, Agouridis AP, et al. The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients. Lipids. 2010;45:445–450.
92. Nakou ES, Filippatos TD, Georgoula M, et al. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin. 2008;24:1919–1929.
93. Takeshita Y, Takamura T, Honda M, et al. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism:a randomised controlled trial. Diabetologia. 2014;57:878–890.
94. Derdemezis C, Filippatos T, Tselepis A, et al. Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels:a pilot study. Expert Opin Pharmacother. 2008;9:1829–1837.
95. Filippatos TD, Elisaf MS. Statin-ezetimibe combination therapy in diabetic individuals. Angiology. 2016;67:507–509.
96. Filippatos TD, Elisaf MS. Effects of ezetimibe/simvastatin combination on metabolic parameters. Int J Cardiol. 2016;202:273–274.
97. Florentin M, Liberopoulos EN, Moutzouri E, et al. The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Curr Med Res Opin. 2011;27:685–692.
98. Kostapanos MS, Elisaf MS, Mikhailidis DP. Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipidemia. J Cardiovasc Pharmacol Ther. 2012;17:427; author reply 8.
99. Moutzouri E, Liberopoulos EN, Florentin M, et al. Effects of statin monotherapy versus statin plus ezetimibe combination on serum uric acid levels. J Cardiovasc Pharmacol Ther. 2013;18:13–18.
100. Moutzouri E, Liberopoulos EN, Tellis CC, et al. Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia. Atherosclerosis. 2013;231:8–14.
101. Moutzouri E, Tellis CC, Rousouli K, et al. Effect of simvastatin or its combination with ezetimibe on Toll-like receptor expression and lipopolysaccharide - induced cytokine production in monocytes of hypercholesterolemic patients. Atherosclerosis. 2012;225:381–387.
102. Agouridis AP, Filippatos TD, Tsimihodimos V, et al. Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism. Expert Rev Cardiovasc Ther. 2011;9:355–366.
103. Agouridis AP, Filippatos TD, Katsiki N. Current lipid-modifying agents. Expert Opin Pharmacother. 2015;16:1117–1118.
104. Filippatos TD, Elisaf MS. Role of ezetimibe in non-alcoholic fatty liver disease. World J Hepatol. 2011;3:265–267.
105. Cannon CP, Blazing MA, Braunwald E. Ezetimibe plus a statin after acute coronary syndromes. N Engl J Med. 2015;373:1476–1477.•• A double-blind randomized clinical trial that showed beneficial effects with the addition of ezetimibe to statin treatment in patients with high cardiovascular risk.
106. Filippatos TD, Elisaf MS. Are lower levels of LDL-cholesterol really better? Looking at the results of IMPROVE-IT:opinions of three experts - III. Hellenic J Cardiol. 2015;56:7–9.
107. Ip CK, Jin DM, Gao JJ, et al. Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events:A meta-analysis of randomized controlled trials. Int J Cardiol. 2015;191:138–148.
108. Florentin M, Liberopoulos EN, Elisaf MS. Ezetimibe-associated adverse effects:what the clinician needs to know. Int J Clin Pract. 2008;62:88–96.
109. Barkas F, Elisaf M, Liberopoulos E, et al. Statin therapy with or without ezetimibe and the progression to diabetes. J Clin Lipidol. 2016;10:306–313.
110. Blazing M, Incidence of new-onset diabetes in the IMPROVE-IT trial:does adding ezetimibe to simvastatin increase risk compared to simvastatin alone? Presented at:European Society of Cardiology Congress; Sep 1, 2015; London, England. https://www.acc.org/latest-in-cardiology/articles/2015/11/20/14/20/incidence-of-new-onset-diabetes-in-the-improve-it-trial?w_nav=Tab.
111. Nozue T, Hattori H, Ogawa K, et al. Effects of statin therapy on plasma proprotein convertase subtilisin/kexin type 9 and sortilin levels in statin-naive patients with coronary artery disease. J Atheroscler Thromb. 2016;23:848–856.
112. Saito I, Azuma K, Kakikawa T, et al. A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia. Lipids Health Dis. 2015;14:40.
113. Ichimori S, Shimoda S, Goto R, et al. Ezetimibe improves glucose metabolism by ameliorating hepatic function in Japanese patients with type 2 diabetes. J Diabetes Investig. 2012;3:179–184.
114. Filippatos T, Milionis HJ. Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert Opin Investig Drugs. 2008;17:1599–1614.
115. Tsimihodimos V, Miltiadous G, Daskalopoulou SS, et al. Fenofibrate:metabolic and pleiotropic effects. Curr Vasc Pharmacol. 2005;3:87–98.
116. Milionis HJ, Elisaf MS, Mikhailidis DP. Treatment of dyslipidaemias in patients with established vascular disease:a revival of the fibrates. Curr Med Res Opin. 2000;16:21–32.
117. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin. 2002;18:269–276.
118. Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome:the FenOrli study. Curr Med Res Opin. 2005;21:1997–2006.
119. Filippatos TD, Derdemezis CS, Georgoula M, et al. Fenofibrate and orlistat, alone or in combination, do not alter plasma visfatin levels in subjects with metabolic syndrome. J Med Sci Res. 2007;2:9–10.
120. Filippatos TD, Gazi IF, Liberopoulos EN, et al. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis. 2007;193:428–437.
121. Filippatos TD, Liberopoulos EN, Kostapanos M, et al. The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes Metab. 2008;10:476–483.
122. Florentin M, Liberopoulos EN, Filippatos TD, et al. Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients:a pilot study. Expert Opin Pharmacother. 2008;9:2741–2750.
123. Agouridis AP, Filippatos TD, Derdemezis CS, et al. Combination of fenofibrate with non-statin drug regimens. Curr Pharm Des. 2010;16:3401–3416.
124. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes:the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357:905–910.
125. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):randomised controlled trial. Lancet. 2005;366:1849–1861.
126. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes:a systematic review and meta-analysis. Lancet. 2010;375:1875–1884.
127. Lee M, Saver JL, Towfighi A, et al. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia:a meta-analysis. Atherosclerosis. 2011;217:492–498.
128. Filippatos TD, Elisaf MS. Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opin Pharmacother. 2011;12:1945–1958.
129. Filippatos TD. A review of time courses and predictors of lipid changes with fenofibric acid-statin combination. Cardiovasc Drugs Ther. 2012;26:245–255.
130. Jones PH, Cusi K, Davidson MH, et al. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus:results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Am J Cardiovasc Drugs. 2010;10:73–84.
131. Stefanutti C, Bucci A, Di Giacomo S, et al. Efficacy, safety and tolerability of combined low-dose simvastatin-fenofibrate treatment in primary mixed hyperlipidaemia. Clin Drug Investig. 2004;24:465–477.
132. Derosa G, Maffioli P, Salvadeo SA, et al. Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. Curr Med Res Opin. 2009;25:1973–1983.
133. Krysiak R, Gdula-Dymek A, Okopien B. Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia. Am J Cardiol. 2011;107(1010–8):e1.
134. Mohiuddin SM, Pepine CJ, Kelly MT, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia:a phase 3, randomized, controlled study. Am Heart J. 2009;157:195–203.
135. Muhlestein JB, May HT, Jensen JR, et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia:the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol. 2006;48:396–401.
136. May HT, Anderson JL, Pearson RR, et al. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined lipid Therapy Regimen study). Am J Cardiol. 2008;101:486–489.
137. Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care. 2002;25:1198–1202.
138. Durrington PN, Tuomilehto J, Hamann A, et al. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract. 2004;64:137–151.
139. Jones PH, Davidson MH, Kashyap ML, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia:a phase 3 study. Atherosclerosis. 2009;204:208–215.
140. Roth EM, Rosenson RS, Carlson DM, et al. Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study. Cardiovasc Drugs Ther. 2010;24:421–428.
141. Roth EM, McKenney JM, Kelly MT, et al. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia:a randomized, double-blind study. Am J Cardiovasc Drugs. 2010;10:175–186.
142. Farnier M, Steinmetz A, Retterstol K, et al. Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg:a double-blind, randomized comparative study. Clin Ther. 2011;33:1–12.
143. Derosa G, Cicero AE, Bertone G, et al. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease:a 12-month, randomized, double-blind, controlled trial. Clin Ther. 2004;26:1599–1607.
144. Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol. 2005;95:462–468.
145. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–1574.• A double-blind randomized clinical trial that showed a possible beneficial effect of adding fenofibrate to statin treatment in the subgroup of diabetic patients with high triglycerides and low high-density lipoprotein cholesterol values.
146. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992;85:37–45.
147. Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med. 2010;363:692–694.
148. Tenenbaum A, Motro M, Fisman EZ, et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med. 2005;165:1154–1160.
149. Bezafibrate Infarction Prevention (BIP) study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease:the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000;102:21–27.
150. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410–418.
151. Frick MH, Elo O, Haapa K, et al. Helsinki heart study:primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237–1245.
152. Scott R, O’Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome:the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009;32:493–498.
153. Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233–244.
154. Aguiar C, Alegria E, Bonadonna RC, et al. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia:A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. Atheroscler Suppl. 2015;19:1–12.
155. Tsimihodimos V, Bairaktari E, Elisaf M. Fibrate-induced increase in serum urea and creatinine levels. Nephrol Dial Transplant. 2002;17:682; author reply.
156. Tsimihodimos V, Miltiadous G, Bairaktari E, et al. Possible mechanisms of the fibrate-induced increase in serum creatinine. Clin Nephrol. 2002;57:407–408.
157. Hottelart C, El Esper N, Rose F, et al. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron. 2002;92:536–541.
158. Forsblom C, Hiukka A, Leinonen ES, et al. Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes:the FIELD Helsinki substudy. Diabetes Care. 2010;33:215–220.
159. Kostapanos MS, Florentin M, Elisaf MS. Fenofibrate and the kidney:an overview. Eur J Clin Invest. 2013;43:522–531.
160. Guo J, Meng F, Ma N, et al. Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia. Am J Cardiol. 2012;110:1296–1301.
161. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005;95:120–122.
162. Bays HE, Jones PH, Mohiuddin SM, et al. Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. J Clin Lipidol. 2008;2:426–435.
163. Filippatos TD, Elisaf MS. Safety considerations with fenofibrate/simvastatin combination. Expert Opin Drug Saf. 2015;14:1481–1493.
164. Schech S, Graham D, Staffa J, et al. Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf. 2007;16:352–358.
165. Taher TH, Dzavik V, Reteff EM, et al. Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. Am J Cardiol. 2002;89:390–394.
166. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. Jama. 2003;289:1681–1690.
167. Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov. 2012;11:367–383.
168. Park SW, Moon YA, Horton JD. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem. 2004;279:50630–50638.
169. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154–156.
170. Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9:its role in LDL metabolism. Trends Biochem Sci. 2007;32:71–77.
171. Cariou B, Le May C, Costet P. Clinical aspects of PCSK9. Atherosclerosis. 2011;216:258–265.
172. Do RQ, Vogel RA, Schwartz GG. PCSK9 Inhibitors:potential in cardiovascular therapeutics. Curr Cardiol Rep. 2013;15:345.
173. Gouni-Berthold I, Descamps OS, Fraass U, et al. Systematic review of published phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia. Br J Clin Pharmacol. 2016. DOI:10.1111/bcp.13066
174. Sattar N, Preiss D, Robinson JG, et al. Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes:a meta-analysis of individual patient data. Lancet Diabetes Endocrinol. 2016;4:403–410.• A meta-analysis that showed the low-density lipoprotein cholesterol lowering efficacy of PCSK9 inhibition in diabetic individuals.
175. Sattar N, Preiss D, Blom D, et al. Evaluation of the one-year efficacy, safety and glycaemic effects of evolocumab (AMG 145) in 4,802 subjects with, at high risk for or at low risk for diabetes mellitus. Presented in the European Association for the Study of Diabetes Stockholm, Sweden, 2015, Sept, 17 Session OP 27.
176. Kereiakes DJ, Robinson JG, Cannon CP, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy:the ODYSSEY COMBO I study. Am Heart J. 2015;169(906–15):e13.
177. Colhoun HM, Ginsberg HN, Robinson JG, et al. No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. Eur Heart J. 2016. doi:10.1093/eurheartj/ehw292.• An analysis of studies with alirocumab that showed no increased risk of diabetes incidence.
178. Achimastos A, Alexandrides T, Alexopoulos D, et al. Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Hormones (Athens). 2016;15:8–14.
179. Kosmas CE, DeJesus E, Rosario D, et al. CETP inhibition:past failures and future hopes. Clin Med Insights Cardiol. 2016;10:37–42.
180. Filippatos TD, Klouras E, Barkas F, et al. Cholesteryl ester transfer protein inhibitors:challenges and perspectives. Expert Rev Cardiovasc Ther. 2016;14:953–962.• A review that presented the evidence regarding the present and future of cholesteryl ester transfer protein inhibitors.
181. Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals:two double-blind, randomised placebo-controlled phase I studies. Lancet. 2007;370:1907–1914.
182. Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009;157(352–60):e2.
183. Kastelein JJ, Besseling J, Shah S, et al. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE):a randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2015;385:2153–2161.
184. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406–2415.
185. Hovingh GK, Kastelein JJ, Van Deventer SJ, et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP):a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2015;386:452–460.
186. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–2122.
187. Barter PJ, Rye KA, Tardif JC, et al. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation. 2011;124:555–562.
188. Siebel AL, Natoli AK, Yap FY, et al. Effects of high-density lipoprotein elevation with cholesteryl ester transfer protein inhibition on insulin secretion. Circ Res. 2013;113:167–175.
189. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–2267.
190. Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203–212.
191. Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”:a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011;9:533–571.
192. Rizzo M, Berneis K, Koulouris S, et al. Should we measure routinely oxidised and atherogenic dense low-density lipoproteins in subjects with type 2 diabetes? Int J Clin Pract. 2010;64:1632–1642.
193. Rizzo M, Rini GB, Berneis K. The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes. Exp Clin Endocrinol Diabetes. 2007;115:477–482.
194. Ansquer JC, Corda C, Le Malicot K, et al. Effects of atorvastatin 10 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients:A 12-week, multicenter, randomized, open-label, parallel-group study. Curr Ther Res Clin Exp. 2009;70:71–93.
195. Tokuno A, Hirano T, Hayashi T, et al. The effects of statin and fibrate on lowering small dense LDL- cholesterol in hyperlipidemic patients with type 2 diabetes. J Atheroscler Thromb. 2007;14:128–132.
196. Rizos CV, Kostapanos MS, Rizos EC, et al. The effect of rosuvastatin on low-density lipoprotein subfractions in patients with impaired fasting glucose. J Cardiovasc Pharmacol Ther. 2015;20:276–283.
197. Florentin M, Tselepis AD, Elisaf MS, et al. Effect of non-statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipidaemia. Curr Vasc Pharmacol. 2010;8:820–830.
198. Kostapanos MS, Milionis HJ, Filippatos TD, et al. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Clin Ther. 2007;29:1403–1414.
199. Agouridis AP, Kostapanos MS, Tsimihodimos V, et al. Effect of rosuvastatin monotherapy or in combination with fenofibrate or omega-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. Int J Clin Pract. 2012;66:843–853.
200. Kostapanos MS, Milionis HJ, Lagos KG, et al. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. Eur J Pharmacol. 2008;590:327–332.
201. Ikewaki K, Tohyama J, Nakata Y, et al. Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men - a nuclear magnetic resonance study. J Atheroscler Thromb. 2004;11:278–285.• A study that showed the beneficial effects of fenofibrate on small dense low-density lipoprotein particles in men with high serum triglycerides concentration.
202. Winkler K, Schewe T, Putz G, et al. Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome:different effects on LDL-profiles. Eur J Clin Invest. 2009;39:463–470.
203. Nozue T, Hattori H, Ogawa K, et al. Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease. Lipids Health Dis. 2016;15:165.
204. Zhang Y, Xu RX, Li S, et al. Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease. Nutr Metab Cardiovasc Dis. 2015;25:426–433.
205. Koren MJ, Kereiakes D, Pourfarzib R, et al. Effect of PCSK9 inhibition by alirocumab on lipoprotein particle concentrations determined by nuclear magnetic resonance spectroscopy. J Am Heart Assoc. 2015. doi:10.1161/JAHA.115.002224
206. Toth PP, Hamon SC, Jones SR, et al. Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method:analysis of 3 randomized trials versus placebo. Lipids Health Dis. 2016;15:28.
207. Si-Tayeb K, Cariou B. PCSK9 Inhibition:Does Lipoprotein Size Matter?. J Am Heart Assoc. 2015. doi:10.1161/JAHA.115.002806.
208. Krauss RM, Wojnooski K, Orr J, et al. Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. J Lipid Res. 2012;53:540–547.
209. Rizzo M, Tomkin GH, Patti AM, et al. Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes. Clinical Lipidology. 2011;6:539–547.
210. Rizzo M, Vekic J, Koulouris S, et al. Effects of rosiglitazone on fasting and postprandial low- and high-density lipoproteins size and subclasses in type 2 diabetes. Angiology. 2010;61:584–590.
211. Berneis K, Rizzo M, Stettler C, et al. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with type 2 diabetes. Expert Opin Pharmacother. 2008;9:343–349.